Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

A Closer Look at IL-17 Inhibitors in Psoriasis : Episode 2

Opinion

Video

March 21, 2025

Mechanism of Action Differences Among IL-17 Inhibitors

Author(s):

Christopher G. Bunick, MD, PhD,James Song, MD, FAAD

Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.

EP: 1.The Role of IL-17 in Psoriasis Pathogenesis

Now Viewing

EP: 2.Mechanism of Action Differences Among IL-17 Inhibitors

EP: 3.Clinical Attributes of IL-17 Inhibitors in Psoriasis

EP: 4.IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis

Video content above is prompted by the following:

How do the mechanisms of action of the approved IL-17 inhibitors differ from one another, and how might these differences translate in terms of efficacy and/or safety?
- Secukinumab (IL-17A inhibitor)—approved 2015
- Ixekizumab (IL-17A inhibitor)—approved 2016
- Brodalumab (IL-17RA inhibitor)—approved 2017
- Bimekizumab (IL-17A and IL-17F inhibitor)—approved 2023